Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03880539 · ClinicalTrials.gov registry record · Phase 4
Bezlotoxumab (BEZLO) In Addition To Standard Of Care (SOC) Vancomycin For The Treatment of Multi-Recurrent Clostridium Difficile Infection
A Phase 4 study, sponsored by University of Kansas Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 4
- Enrollment target
NCT03880539 is a Phase 4 study that has completed, run by University of Kansas Medical Center. The registered enrollment target is 4 participants.
The verdict
NCT03880539, a Phase 4 study, has completed, sponsored by University of Kansas Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is a research study to collect information from people that have Clostridium difficile infection (CDI) and are treated with a standard antibiotic treatment in which the antibiotic dose is gradually reduced over 6 weeks and bezlotoxumab (BEZLO), an approved monoclonal antibody targeting C. difficile toxin, which has shown to reduce CID recurrence when used in combination with standard antibiotic treatment.
Interventions
- DRUG bezlotoxumab
- DRUG Vancomycin Oral
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2019-06-25 |
| Est. Completion | 2021-11-18 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03880539
The ClinicalTrials.gov registry entry for NCT03880539 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which bezlotoxumab is the first listed.
NCT03880539 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03880539 about?
NCT03880539 is a clinical study titled "Bezlotoxumab (BEZLO) In Addition To Standard Of Care (SOC) Vancomycin For The Treatment of Multi-Recurrent Clostridium Difficile Infection". This is a research study to collect information from people that have Clostridium difficile infection (CDI) and are treated with a standard antibiotic treatment in which the antibiotic dose is gradually reduced over 6 weeks and bezlotoxumab (BEZLO), an approved monoclonal antibody targeting C. diffi...
What is the current status of trial NCT03880539?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 4 participants. The study started on 2019-06-25. Estimated completion is 2021-11-18.
What interventions are being tested in trial NCT03880539?
The interventions under investigation include: bezlotoxumab (DRUG), Vancomycin Oral (DRUG).
Who is sponsoring clinical trial NCT03880539?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.